Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 6
1975 39
1976 83
1977 30
1978 60
1979 74
1980 66
1981 101
1982 116
1983 112
1984 144
1985 154
1986 162
1987 162
1988 165
1989 203
1990 209
1991 194
1992 211
1993 281
1994 244
1995 239
1996 233
1997 264
1998 250
1999 280
2000 298
2001 255
2002 223
2003 253
2004 243
2005 284
2006 303
2007 313
2008 356
2009 340
2010 337
2011 338
2012 317
2013 368
2014 396
2015 366
2016 368
2017 375
2018 409
2019 427
2020 467
2021 447
2022 409
2023 332
2024 160

Text availability

Article attribute

Article type

Publication date

Search Results

11,484 results

Results by year

Filters applied: . Clear all
Page 1
Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer.
Couto RD, Fernandes BJD. Couto RD, et al. Curr Drug Res Rev. 2021;13(2):86-89. doi: 10.2174/2589977513666210127094222. Curr Drug Res Rev. 2021. PMID: 33504322 Review.
Naltrexone (NTX) is an opioid antagonist that inhibits cell proliferation in vivo when administered in low doses. Naltrexone in low doses can reduce tumor growth by interfering with cell signalling as well as by modifying the immune system. ...
Naltrexone (NTX) is an opioid antagonist that inhibits cell proliferation in vivo when administered in low doses. Naltrexone i …
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Younger J, Parkitny L, McLain D. Younger J, et al. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Clin Rheumatol. 2014. PMID: 24526250 Free PMC article. Review.
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the cen …
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multi …
Naltrexone at low doses (LDN) and its relevance to cancer therapy.
Liu WM, Dalgleish AG. Liu WM, et al. Expert Rev Anticancer Ther. 2022 Mar;22(3):269-274. doi: 10.1080/14737140.2022.2037426. Epub 2022 Feb 7. Expert Rev Anticancer Ther. 2022. PMID: 35107043 Review.
It was noted that in certain patients being treated with naltrexone for an opioid addiction many reported significant secondary benefit when being weaned off naltrexone. This group of patients had chronic inflammatory and autoimmune conditions and reported improveme …
It was noted that in certain patients being treated with naltrexone for an opioid addiction many reported significant secondary benef …
Naltrexone and Alcohol Use.
Avery J. Avery J. Am J Psychiatry. 2022 Dec 1;179(12):886-887. doi: 10.1176/appi.ajp.20220821. Am J Psychiatry. 2022. PMID: 36453035 No abstract available.
Naltrexone: A Pan-Addiction Treatment?
Aboujaoude E, Salame WO. Aboujaoude E, et al. CNS Drugs. 2016 Aug;30(8):719-33. doi: 10.1007/s40263-016-0373-0. CNS Drugs. 2016. PMID: 27401883 Review.
Despite the very different presentations within and between both addiction categories, the data, as a whole, show consistency in favor of naltrexone's relative efficacy and safety. Given the potential benefit and good tolerability revealed in the studies, the high m …
Despite the very different presentations within and between both addiction categories, the data, as a whole, show consistency in favor of …
Naltrexone in alcohol dependence.
Hartmann PM. Hartmann PM. Am Fam Physician. 1997 Apr;55(5):1877-9, 1883-4. Am Fam Physician. 1997. PMID: 9105212 Review.
Naltrexone is a narcotic antagonist that has been shown to reduce alcohol craving and alcohol use in patients with alcohol dependence. ...The latter complication occurs only at dosages much higher than the 50 mg per day recommended for treatment of alcohol dependence. Alco …
Naltrexone is a narcotic antagonist that has been shown to reduce alcohol craving and alcohol use in patients with alcohol dependence …
[Naltrexone].
Schifano F, Murri R, Gava R. Schifano F, et al. G Clin Med. 1989 May;70(5):379-84. G Clin Med. 1989. PMID: 2666229 Review. Italian. No abstract available.
Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures.
Liubchenko K, Kordbacheh K, Khajehdehi N, Visnjevac T, Ma F, Khan JS, Storey M, Abd-Elsayed A, Visnjevac O. Liubchenko K, et al. Adv Ther. 2021 Feb;38(2):904-924. doi: 10.1007/s12325-020-01591-9. Epub 2020 Dec 18. Adv Ther. 2021. PMID: 33337537 Review.
BACKGROUND: Naltrexone (NTX) is an opioid antagonist traditionally used as a treatment for alcohol and opioid use disorders, but various studies have documented its involvement in cancer progression, exploring possible anticancer potential, when administered at high doses …
BACKGROUND: Naltrexone (NTX) is an opioid antagonist traditionally used as a treatment for alcohol and opioid use disorders, but vari …
Is there a therapeutic potential in combining bupropion and naltrexone in schizophrenia?
El Hayek SA, Shatila MA, Adnan JA, Geagea LE, Kobeissy F, Talih FR. El Hayek SA, et al. Expert Rev Neurother. 2022 Sep;22(9):737-749. doi: 10.1080/14737175.2022.2124369. Epub 2022 Sep 14. Expert Rev Neurother. 2022. PMID: 36093756 Review.
INTRODUCTION: A sustained-release tablet composed of a combination of the dopamine and norepinephrine reuptake inhibitor bupropion (BUP) and the -opioid receptor antagonist naltrexone (NAT) is marketed under the brand name Contrave by Orexigen Therapeutics for appetite con …
INTRODUCTION: A sustained-release tablet composed of a combination of the dopamine and norepinephrine reuptake inhibitor bupropion (BUP) and …
What place does naltrexone have in the treatment of alcoholism?
Rohsenow DJ. Rohsenow DJ. CNS Drugs. 2004;18(9):547-60. doi: 10.2165/00023210-200418090-00001. CNS Drugs. 2004. PMID: 15222772 Review.
Naltrexone also reduces urges to drink and makes any slips back into drinking less pleasant. ...Many alcohol-dependent individuals are medically ineligible or are unwilling to take naltrexone, many who start naltrexone do not continue with it and many who com …
Naltrexone also reduces urges to drink and makes any slips back into drinking less pleasant. ...Many alcohol-dependent individuals ar …
11,484 results
You have reached the last available page of results. Please see the User Guide for more information.

Searches related to "naltrexone"